Clinical Trials Logo

Depressive Disorder, Major clinical trials

View clinical trials related to Depressive Disorder, Major.

Filter by:

NCT ID: NCT03672175 Not yet recruiting - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder

Start date: September 2018
Phase: Phase 3
Study type: Interventional

This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult subjects with major depressive disorder

NCT ID: NCT03670823 Not yet recruiting - Major Depression Clinical Trials

Prediction of SSRI Treatment in Major Depression.

Start date: October 1, 2018
Phase:
Study type: Observational

This project will combine the data collected from EEG, Eye tracking, structural and functional MRI scans and neuropsychological performance from patients with major depression receiving SSRI treatment. The purpose of this research is to predict the success of the SSRI treatment and to categorize patients into sub-groups according to similar patterns of brain activation to personalize treatment.

NCT ID: NCT03668600 Enrolling by invitation - Clinical trials for Depressive Disorder, Major

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Start date: August 23, 2018
Phase: Phase 3
Study type: Interventional

Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.

NCT ID: NCT03666494 Not yet recruiting - Depression Clinical Trials

Ketamine Co-induction for Patients With Major Depressive Disorder

Start date: December 2018
Phase: Phase 4
Study type: Interventional

Ketamine hydrochloride, an anesthetic medication, has been demonstrated to acutely and rapidly improve depressive symptoms but not yet been adequately studied for this effect when used as part of a general anesthetic for surgery. This proposed single-centre, double-blinded, randomized clinical trial of adult patients with depression presenting for gynecologic surgery would compare severity of depressive symptoms between patients receiving and not receiving ketamine as part of their general anesthetic.

NCT ID: NCT03666390 Recruiting - Clinical trials for Major Depressive Disorder

Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide

Start date: September 10, 2018
Phase: N/A
Study type: Interventional

Depression and suicide are two leading mental health and public health issues in Taiwan. However, until now, the optimal treatment for refractory depression and suicide is still lacking. Previous USA studies suggested a low dose NMDA antagonist Ketamine infusion can significantly reduce depression and suicide. In our study, we firstly investigate the anti-suicide and anti-depressive effects of ketamine in Taiwan. If we can find the similar antidepressant and anti-suicide of ketamine in Taiwanese, this result will have a great influence in the current suicide and depression prevention programs.

NCT ID: NCT03665831 Not yet recruiting - Clinical trials for Major Depressive Disorder

Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults

Start date: October 2018
Phase: N/A
Study type: Interventional

In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 diagnosed with mild to early-moderate AD and comorbid MDD who have been unable to tolerate or failed to respond to antidepressant medications. The coil was designed to stimulate deeper regions of the left DLPFC. The investigators propose that active stimulation with the H1 coil will result in higher remission rates than placebo stimulation but will have a similar tolerability and safety profile.

NCT ID: NCT03658330 Completed - Clinical trials for Major Depressive Disorder

Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

Start date: May 2016
Phase: Phase 2
Study type: Interventional

To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.

NCT ID: NCT03653858 Not yet recruiting - Clinical trials for Treatment-resistant Depression

Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression

FORESEE III
Start date: September 3, 2018
Phase: N/A
Study type: Interventional

The primary objective of this multicenter, randomized, sham-controlled, double blind (patient and observer blinded) clinical trial is to assess the antidepressant effect of Deep Brain Stimulation (DBS) in patients with treatment resistant major depression using the Boston Scientific implantable Vercise™ GEVIA™ DBS system compared to sham.

NCT ID: NCT03652597 Recruiting - Clinical trials for Major Depressive Disorder

Neuro-Cardiac-Guided Transcranial Magnetic Stimulation: Replication and Dose-response.

Start date: March 6, 2018
Phase: N/A
Study type: Interventional

Autonomic regulation is disturbed in patients with major depressive disorder (MDD), indicated by a higher heart rate (HR) and lower heart rate variability (HRV). Moreover, the heart seems to be functionally connected via the vagus nerve (VN) to other brain structures that are dysregulated in depression, such as the subgenual anterior cingulate cortex (sgACC), and the dorsolateral prefrontal cortex (DLPFC), suggesting dysregulated network function in MDD. In line with this network dysregulation hypothesis of MDD, optimal transcranial magnetic stimulation (TMS) sites are currently thought to be those that show functional connectivity to the sgACC such as the DLPFC and multiple studies have shown that stimulation of the DLPFC, sgACC and nervus vagus decreased heart rate, suggestive of parasymphatetic action. It is hypothesized that this influence on parasympathetic activity can be used as a functional outcome measure reflecting adequate targeting of the DLPFC-sgACC network, similar to the motor evoked potential (MEP) as functional key measure for primary motor cortex stimulation. Recently, a pilot study was conducted, proposing a new functional neuronavigation method for localizing the frontal area representation of DLPFC-sgACC connectivity using HR, called: Neuro-Cardiac-Guided TMS (NCG-TMS), which is being replicated in the current study. .

NCT ID: NCT03646058 Not yet recruiting - Suicidal Ideation Clinical Trials

Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode

BUPRIS
Start date: September 2019
Phase: Phase 3
Study type: Interventional

This study aims at investigating if adjunctive buprenorphine at low dose to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode, and at determining the most effective dose.